Protalix BioTherapeutics (TASE:PLX) - Aandelenkoers, Nieuws & Analyse

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

PLX Overzicht aandelen

A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.

Over het bedrijf

PLX fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Beloningen

Earnings are forecast to grow 129.73% per year

Earnings have grown 25.3% per year over the past 5 years

Trading at good value compared to peers and industry

Risicoanalyse

Has less than 1 year of cash runway

Negative shareholders equity

Highly volatile share price over the past 3 months

Shareholders have been diluted in the past year

Protalix BioTherapeutics, Inc. Concurrenten

Kamada

TASE:KMDA

₪1.2b

Can-Fite BioPharma

TASE:CANF

₪71.5m

Evogene

TASE:EVGN

₪53.4m

Smart Agro -

TASE:SMAG

₪6.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Protalix BioTherapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$7.33
52 Week Hoogtepunt	US$7.80
52 Week Laag	US$3.15
Bèta	1.47
11 maand verandering	28.98%
3 maanden verandering	75.79%
1 Jaar Verandering	97.55%
33 jaar verandering	-16.86%
5 jaar verandering	-59.71%
Verandering sinds IPO	-97.70%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	PLX	IL Biotechs	IL Markt
7D	-0.1%	0.9%	1.6%
1Y	97.5%	-4.9%	27.5%

Rendement versus industrie: PLX exceeded the IL Biotechs industry which returned -49.3% over the past year.

Rendement versus markt: PLX exceeded the IL Market which returned -25.9% over the past year.

Prijsvolatiliteit

Is PLX's price volatile compared to industry and market?
PLX volatility
PLX Average Weekly Movement	9.4%
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.1%
10% most volatile stocks in IL Market	7.4%
10% least volatile stocks in IL Market	3.0%

Stabiele aandelenkoers: PLX's share price has been volatile over the past 3 months.

Volatiliteit in de loop van de tijd: PLX's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of IL stocks.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1993	195	Dror Bashan	www.protalix.com

Protalix BioTherapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Protalix BioTherapeutics zich tot de beurswaarde?
PLX fundamentele statistieken
Marktkapitalisatie	₪407.53m
Inkomsten(TTM)	-₪54.09m
Inkomsten(TTM)	₪172.62m

2.4x

P/S-verhouding

-7.5x

Koers/Winstverhouding

Is PLX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
PLX resultatenrekening (TTM)
Inkomsten	US$47.64m
Kosten van inkomsten	US$19.59m
Brutowinst	US$28.05m
Overige uitgaven	US$42.97m
Inkomsten	-US$14.93m

Laatst gerapporteerde inkomsten

Dec 31, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.26
Brutomarge	58.87%
Nettowinstmarge	-31.33%
Schuld/Eigen Vermogen Verhouding	-264.9%

Hoe presteerde PLX op de lange termijn?

Bekijk historische prestaties en vergelijking

This company listing is no longer active

PLX Overzicht aandelen

Beloningen

Risicoanalyse

Protalix BioTherapeutics, Inc. Concurrenten

TASE:KMDA

₪1.2b

TASE:CANF

₪71.5m

TASE:EVGN

₪53.4m

TASE:SMAG

₪6.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Protalix BioTherapeutics to Delist Its Common Stock from the Tel Aviv Stock Exchange

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of A Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

Third quarter 2022 earnings released: US$0.072 loss per share (vs US$0.092 loss in 3Q 2021)

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease

Protalix BioTherapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.25 loss in 2Q 2021)

Recent updates

Protalix BioTherapeutics to Delist Its Common Stock from the Tel Aviv Stock Exchange

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of A Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

Third quarter 2022 earnings released: US$0.072 loss per share (vs US$0.092 loss in 3Q 2021)

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease

Protalix BioTherapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.25 loss in 2Q 2021)

Protalix BioTherapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Protalix BioTherapeutics, Inc. Appoints Shmuel "Muli" Ben Zvi to Its Board of Directors and Audit Committee and Compensation Committee

First quarter 2022 earnings released: US$0.05 loss per share (vs US$0.14 loss in 1Q 2021)

Protalix BioTherapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

President recently bought ₪328k worth of stock

Protalix Biotherapeutics, Inc. Announces Topline Results from BALANCE Pivotal Phase III Clinical Trial Evaluating pegunigalsidase alfa

Full year 2021 earnings released: US$0.63 loss per share (vs US$0.22 loss in FY 2020)

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Submission of Marketing Authorization Application to the European Medicines Agency for PRX-102 for Treatment of Fabry Disease

Third quarter 2021 earnings released: US$0.092 loss per share (vs US$0.14 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.25 loss per share (vs US$0.13 loss in 2Q 2020)

Protalix BioTherapeutics, Inc. Announces Submission of Type A Meeting Request to the FDA

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.096 profit in 1Q 2020)

Protalix Biotherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from Fda

Full year 2020 earnings released: US$0.22 loss per share (vs US$1.23 loss in FY 2019)

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Positive Topline Results from Bright Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 Mg/Kg Every Four Weeks for Treatment of Fabry Disease

Protalix Biotherapeutics Enters into an Exclusive Partnership with Sarcomed USA to Develop Alidornase Alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery

Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021

New 90-day high: ₪15.05

Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium™ 2021

New 90-day high: ₪13.60

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Results of Bridge Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announces Extension of Pdufa Date for Pegunigalsidase Alfa for the Propose Treatment of Fabry Disease

New 90-day low: ₪11.03

Third quarter earnings released

Chiesi Farmaceutici S.P.A. and Protalix BioTherapeutics, Inc Announce Launch of an Expanded Access Program (Eap) in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

New 90-day high: ₪13.79

Protalix Biotherapeutics and Chiesi Farmaceutici Announce Successful Pre-BLA Meeting with FDA for Accelerated Approval of Pegunigalsidase Alfa for the Treatment of Fabry Disease in the United States

Protalix Biotherapeutics Regains Compliance with NYSE American Continued Listing Standards

New 90-day low - ₪11.41

New 90-day low - ₪11.66

First half earnings released

Protalix BioTherapeutics, Inc. to Report Q2, 2020 Results on Aug 10, 2020

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Protalix BioTherapeutics, Inc. Samenvatting

2.4x

-7.5x

Inkomsten en omzet